JP2004537532A - 疾患治療用のキヌクリジン置換多環式へテロアリール - Google Patents

疾患治療用のキヌクリジン置換多環式へテロアリール Download PDF

Info

Publication number
JP2004537532A
JP2004537532A JP2003503624A JP2003503624A JP2004537532A JP 2004537532 A JP2004537532 A JP 2004537532A JP 2003503624 A JP2003503624 A JP 2003503624A JP 2003503624 A JP2003503624 A JP 2003503624A JP 2004537532 A JP2004537532 A JP 2004537532A
Authority
JP
Japan
Prior art keywords
pyridine
azabicyclo
oct
carboxamide
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003503624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004537532A5 (https=
Inventor
ドン・ジー・ウィシュカ
スティーブン・シー・ライツ
デイビッド・ダブリュー・ピオトロースキー
ビンセント・イー・グロッピ・ジュニア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of JP2004537532A publication Critical patent/JP2004537532A/ja
Publication of JP2004537532A5 publication Critical patent/JP2004537532A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2003503624A 2001-06-12 2002-06-06 疾患治療用のキヌクリジン置換多環式へテロアリール Withdrawn JP2004537532A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US29770801P 2001-06-12 2001-06-12
US29771201P 2001-06-12 2001-06-12
US29771101P 2001-06-12 2001-06-12
US29770901P 2001-06-12 2001-06-12
US29771001P 2001-06-12 2001-06-12
US32859601P 2001-10-11 2001-10-11
US37349502P 2002-04-18 2002-04-18
PCT/US2002/016568 WO2002100857A1 (en) 2001-06-12 2002-06-06 Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease

Publications (2)

Publication Number Publication Date
JP2004537532A true JP2004537532A (ja) 2004-12-16
JP2004537532A5 JP2004537532A5 (https=) 2006-01-05

Family

ID=27569623

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003503624A Withdrawn JP2004537532A (ja) 2001-06-12 2002-06-06 疾患治療用のキヌクリジン置換多環式へテロアリール

Country Status (17)

Country Link
US (1) US7067515B2 (https=)
EP (1) EP1406901A1 (https=)
JP (1) JP2004537532A (https=)
KR (1) KR20040018266A (https=)
CN (1) CN1511154A (https=)
AR (1) AR036040A1 (https=)
BR (1) BR0210384A (https=)
CA (1) CA2445467A1 (https=)
CO (1) CO5540302A2 (https=)
CZ (1) CZ20033377A3 (https=)
EA (1) EA200301216A1 (https=)
IL (1) IL159344A0 (https=)
MX (1) MXPA03011484A (https=)
NO (1) NO20035522D0 (https=)
PE (1) PE20030431A1 (https=)
PL (1) PL367311A1 (https=)
WO (1) WO2002100857A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509964A (ja) * 2005-09-23 2009-03-12 メモリー・ファーマシューティカルズ・コーポレイション インダゾール類、ベンゾチアゾール類、ベンゾイソオキサゾール類、ピラゾロピリジン類、イソチアゾロピリジン類、およびそれらの製造と用途
JP2016079114A (ja) * 2014-10-14 2016-05-16 国立大学法人 名古屋工業大学 ジフルオロメチルアセチレン化合物類及びその製造方法

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2462453C (en) * 2001-10-02 2009-07-28 Pharmacia & Upjohn Company Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
DE10164139A1 (de) * 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
MXPA04012439A (es) 2002-06-10 2005-04-19 Bayer Healthcare Ag Amidas de acidos 2-heteroarilcarboxilicos.
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
MXPA05003317A (es) 2002-09-25 2005-07-05 Memory Pharm Corp Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos.
AU2003269413A1 (en) * 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
WO2004039815A2 (en) * 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
BR0317019A (pt) * 2002-12-06 2005-10-25 Pharmacia & Upjohn Co Llc Sais cristalinos fumarato de 1-azabiciclo[2.2.2]oct-substituìdo-furo[2,3-c]piridinil- carboxamida e suas composições e preparações
EP1598355A4 (en) * 2003-01-08 2010-01-27 Mitsubishi Tanabe Pharma Corp THERAPEUTIC ACTIVE FOR THE TREATMENT OF SCHIZOPHRENIA
EP1587511A2 (en) * 2003-01-22 2005-10-26 Pharmacia & Upjohn Company LLC Treatment of diseases with alpha-7 nach receptor full agonists
DE10334724A1 (de) * 2003-07-30 2005-02-24 Bayer Healthcare Ag N-Biarylamide
RU2389729C2 (ru) 2003-12-22 2010-05-20 Мемори Фармасьютиклз Корпорейшн 1н-индазолы, 1, 2-бензизоксазолы и 1, 2-бензизотиазолы, их получение и применение
WO2005063296A2 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
US7365193B2 (en) 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
US20050171079A1 (en) * 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
EP1735306A2 (en) 2004-03-25 2006-12-27 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
CA2567977A1 (en) 2004-04-22 2006-01-05 Memory Pharmaceutical Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
NZ551712A (en) 2004-05-07 2010-07-30 Memory Pharm Corp 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparations and uses thereof
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
CA2591817A1 (en) 2004-12-22 2006-06-29 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
WO2007027855A2 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
WO2007103308A2 (en) 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8697722B2 (en) * 2007-11-02 2014-04-15 Sri International Nicotinic acetylcholine receptor modulators
LT2889033T (lt) 2008-11-19 2018-07-10 Forum Pharmaceuticals Inc. Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP5808319B2 (ja) * 2009-05-11 2015-11-10 フォルム ファーマシューティカルズ、インコーポレイテッド アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療
WO2011020712A2 (en) * 2009-08-18 2011-02-24 Universite Libre De Bruxelles Oligothiophenes derivatives
WO2011022692A2 (en) * 2009-08-20 2011-02-24 University Of Tennessee Research Foundation, The Furanopyridine cannabinoid compounds and related methods of use
RU2560729C2 (ru) 2010-01-11 2015-08-20 АСТРАЕА ТЕРАПЕУТИКС, ЭлЭлСи Модуляторы никотиновых ацетилхолиновых рецепторов
GB201002563D0 (en) 2010-02-15 2010-03-31 Cambridge Entpr Ltd Compounds
PE20170923A1 (es) 2010-05-17 2017-07-12 Forum Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado
KR101928505B1 (ko) * 2011-01-28 2018-12-12 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
BR112013032044A2 (pt) 2011-06-30 2016-12-13 Toray Industries antiprurítico
EP3461481A1 (en) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
EP2876109A4 (en) * 2012-07-23 2016-03-16 Yuhan Corp CONDENSED RING CONNECTION WITH FURAN OR SALT AND PHARMACEUTICAL COMPOSITIONS THEREWITH
CN106883270B (zh) 2015-11-26 2019-03-26 财团法人工业技术研究院 有机金属化合物、包含其的有机发光装置
CN112839648B (zh) 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
CN115974833B (zh) * 2022-12-28 2024-08-02 苏州汉德创宏生化科技有限公司 一种3-氨基噻吩草酸盐的制备方法

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ194747A (en) 1979-08-29 1988-11-29 Schering Ag 9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives
ZA832549B (en) 1982-04-14 1988-09-28 Beecham Group Plc Pharmaceutically active compounds
FR2531083B1 (fr) 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
WO1985001048A1 (en) 1983-08-26 1985-03-14 Sandoz Ag Aromatic esters or amides of carboxylic acid and sulfonic acid
US5175173A (en) 1983-12-22 1992-12-29 Sun Jung Hui Carboxamides useful as antiemetic or antipsychotic agents
US4888353A (en) 1986-02-28 1989-12-19 Erbamont, Inc. Carboxamides useful as antiemetic or antipsychotic agents
FR2557110B1 (fr) 1983-12-23 1989-11-24 Sandoz Sa Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments
EP0201165B1 (en) 1985-03-14 1994-07-20 Beecham Group Plc Medicaments for the treatment of emesis
US4937247A (en) 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
GB8520616D0 (en) 1985-08-16 1985-09-25 Beecham Group Plc Compounds
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
EP0254584B1 (en) 1986-07-25 1992-10-07 Beecham Group Plc Azabicyclic compounds, process for their preparation, and their pharmaceutical use
HU895334D0 (en) 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions
JPS63277622A (ja) 1986-12-17 1988-11-15 グラクソ、グループ、リミテッド 医薬
DE3751404T2 (de) 1986-12-17 1995-12-21 Glaxo Group Ltd Verwendung von heterocyclischen Verbindungen zur Behandlung von Bewusstseinsstörungen.
US5322951A (en) 1987-01-05 1994-06-21 Beecham Group, P.L.C. Certain 1-(2,3-dihydro-indole)carbonyl intermediates
GB8806990D0 (en) 1988-03-23 1988-04-27 Beecham Group Plc Novel compounds
GB8701022D0 (en) 1987-01-19 1987-02-18 Beecham Group Plc Treatment
US4835162A (en) 1987-02-12 1989-05-30 Abood Leo G Agonists and antagonists to nicotine as smoking deterents
EP0287196B1 (en) 1987-02-18 1994-11-23 Beecham Group Plc Indole derivatives, process for their preparation and pharmaceutical compositions containing them
DE3822792C2 (de) 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
US4921982A (en) 1988-07-21 1990-05-01 Eli Lilly And Company 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids useful as intermediates for 5-HT3 antagonists
NZ227229A (en) 1987-12-10 1991-03-26 Duphar Int Res Indole derivatives and pharmaceutical compositions
AU611976B2 (en) 1987-12-24 1991-06-27 John Wyeth & Brother Limited Aroyl urea and carbamic acid derivatives of azabicyclo compounds
US4863919A (en) 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
US4924010A (en) 1988-02-04 1990-05-08 Rorer Pharmaceutical Corporation Benzoxepins as intermediates to 5HT3 antagonists
DE3810552A1 (de) 1988-03-29 1989-10-19 Sandoz Ag Ester und amide von indol-, benzo(b)thiopen-, benzo(b)furancarbonsaeuren oder 4-amino-2-methoxy-benzolsaeuren mit n-heterocyclischen oder n-heterobicyclischen alkoholen oder aminen, verfahren zu deren herstellung sie enthaltende pharmazeutische zusammensetzungen sowie applikator zur verabreichung derselben
US4863921A (en) 1988-04-27 1989-09-05 Rorer Pharmaceutical Corporation Dibenzofurancarboxamides and their pharmaceutical compositions and methods
US5246942A (en) 1988-04-27 1993-09-21 Rhone-Poulenc Rorer Pharmaceuticals Inc. Pharmaceutically useful dibenzofurancarboxamides of specific stereo-configuration
US4920227A (en) 1988-11-29 1990-04-24 Rorer Pharmaceutical Corp. Benzobicyclic carboxamide 5-HT3 antagonists
US4933445A (en) 1988-11-29 1990-06-12 Rorer Pharmaceutical Corporation Heteroazabenzobicyclic carboxamide 5-HT3 antagonists
US4920219A (en) 1988-11-29 1990-04-24 Rorer Pharmaceutical Corp. Substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their use as pharmacological agents
WO1990014347A1 (fr) 1989-05-24 1990-11-29 Nippon Shinyaku Co., Ltd. Derives d'indole et medicament
EP0402056A3 (en) 1989-06-06 1991-09-04 Beecham Group p.l.c. Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US4935511A (en) 1989-09-26 1990-06-19 Rorer Pharmaceutical Corporation Benzoxazine and benzoxazepine carboxamide 5-HT3 antagonists
GB2236751B (en) 1989-10-14 1993-04-28 Wyeth John & Brother Ltd Heterocyclic compounds
GB8928837D0 (en) 1989-12-21 1990-02-28 Beecham Group Plc Pharmaceuticals
EP0436245A1 (en) 1989-12-27 1991-07-10 Duphar International Research B.V Substituted 3,4-annelated benzimidazol-2(1H)-ones
GB9009542D0 (en) 1990-04-27 1990-06-20 Beecham Group Plc Novel compounds
AU7618991A (en) 1990-05-14 1991-11-14 Syntex (U.S.A.) Inc. Novel tricyclic compounds
AU8405891A (en) 1990-08-31 1992-03-30 Nippon Shinyaku Co. Ltd. Indole derivative and medicine
US5200415A (en) * 1990-11-01 1993-04-06 Asahi Kasei Kogyo Kabushiki Kaisha Pyrazolo[1,5-a]pyridine-3-carboxylic acid derivatives and their pharmaceutical use
US5189041A (en) 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists
GB9027098D0 (en) 1990-12-13 1991-02-06 Beecham Group Plc Pharmaceuticals
HU211081B (en) 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
US5114947A (en) 1990-12-27 1992-05-19 Erbamont Inc. Method for alleviating anxiety using benzobicyclic carboxamides
GB9028105D0 (en) 1990-12-27 1991-02-13 Erba Carlo Spa Process for the preparation of substituted benzofuran derivatives
IL100432A (en) 1990-12-27 1996-01-19 Erba Carlo Spa Dihydrobenzofuran carboxamide derivatives their preparation and pharmaceutical compositions containing them
US5260303A (en) 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
DE4115215A1 (de) 1991-05-10 1992-11-12 Merck Patent Gmbh Indolderivate
GB9120628D0 (en) 1991-09-27 1991-11-06 Fujisawa Pharmaceutical Co Pyrrolobenzoxazine derivatives and process for preparation thereof
JP2553020B2 (ja) * 1991-11-07 1996-11-13 吉富製薬株式会社 キヌクリジン化合物およびその医薬用途
JPH05310732A (ja) 1992-03-12 1993-11-22 Mitsubishi Kasei Corp シンノリン−３−カルボン酸誘導体
JP2699794B2 (ja) 1992-03-12 1998-01-19 三菱化学株式会社 チエノ〔３，２−ｂ〕ピリジン誘導体
US5273972A (en) 1992-03-26 1993-12-28 A. H. Robins Company, Incorporated [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates
DE69230110T2 (de) * 1992-04-10 2000-06-15 Asahi Kasei Kogyo K.K., Osaka An drei ringen substituierte tetrahydropyridin-derivate
SE9201478D0 (sv) 1992-05-11 1992-05-11 Kabi Pharmacia Ab Heteroaromatic quinuclidinenes, their use and preparation
US5300512A (en) 1992-06-24 1994-04-05 G. D. Searle & Co. Benzimidazole compounds
US5977144A (en) 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
IT1265057B1 (it) * 1993-08-05 1996-10-28 Dompe Spa Tropil 7-azaindolil-3-carbossiamidi
GB9406857D0 (en) 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
US5510478A (en) 1994-11-30 1996-04-23 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
GB9507882D0 (en) 1995-04-18 1995-05-31 Pharmacia Spa Substituted dihydrobenzofuran derivatives as 5-ht4 agonists
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
ES2109190B1 (es) * 1996-03-22 1998-07-01 Univ Madrid Complutense Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht
FR2769915B1 (fr) 1997-10-21 2000-10-13 Synthelabo Derives d'indazole tricycliques, leur preparation et leur application en therapeutique
AU4980200A (en) 1999-05-27 2000-12-18 Pharmacia & Upjohn Company Methods and compositions for measuring ion channel conductance
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
JP4616971B2 (ja) 2000-07-18 2011-01-19 田辺三菱製薬株式会社 １−アザビシクロアルカン化合物およびその医薬用途
US20020016334A1 (en) 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
CA2462453C (en) * 2001-10-02 2009-07-28 Pharmacia & Upjohn Company Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
ES2348282T3 (es) 2002-04-18 2010-12-02 Astrazeneca Ab Compuestos de tienilo.
US7417049B2 (en) 2002-04-18 2008-08-26 Astrazeneca Ab Furyl compounds
NZ561993A (en) 2002-04-18 2008-09-26 Astrazeneca Ab Spiroazabicyclic heterocyclic amines as potent ligands for nicotinic acetylcholine receptors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509964A (ja) * 2005-09-23 2009-03-12 メモリー・ファーマシューティカルズ・コーポレイション インダゾール類、ベンゾチアゾール類、ベンゾイソオキサゾール類、ピラゾロピリジン類、イソチアゾロピリジン類、およびそれらの製造と用途
JP2016079114A (ja) * 2014-10-14 2016-05-16 国立大学法人 名古屋工業大学 ジフルオロメチルアセチレン化合物類及びその製造方法

Also Published As

Publication number Publication date
PE20030431A1 (es) 2003-05-26
PL367311A1 (en) 2005-02-21
BR0210384A (pt) 2004-06-29
EA200301216A1 (ru) 2004-06-24
IL159344A0 (en) 2004-06-01
CN1511154A (zh) 2004-07-07
MXPA03011484A (es) 2004-03-18
CA2445467A1 (en) 2002-12-19
NO20035522D0 (no) 2003-12-11
AR036040A1 (es) 2004-08-04
CO5540302A2 (es) 2005-07-29
EP1406901A1 (en) 2004-04-14
CZ20033377A3 (cs) 2004-11-10
WO2002100857A1 (en) 2002-12-19
US20030045540A1 (en) 2003-03-06
US7067515B2 (en) 2006-06-27
KR20040018266A (ko) 2004-03-02

Similar Documents

Publication Publication Date Title
US7067515B2 (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease
JP4371811B2 (ja) 疾患治療のためのアザ二環式置換縮合ヘテロアリール化合物
EP1425286B1 (en) Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases
US6828330B2 (en) Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease
MXPA04008038A (es) Carboxamidas heteroaromaticas biciclicas condensadas con puente de n para el tratamiento de enfermedades.
US20040147522A1 (en) Compounds having both alpha7 nicotinic agonist activity and 5HT3 antagonist activity for the treatment of CNS diseases
JP2005511574A6 (ja) Ｎａｃｈｒアゴニストとしてのｎ−アザビシクロ−置換ヘテロ二環式カルボキサミド
JP2005511574A (ja) Ｎａｃｈｒアゴニストとしてのｎ−アザビシクロ−置換ヘテロ二環式カルボキサミド
AU2002348498A1 (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease
AU2002339957A1 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
UA77447C2 (en) Azabicyclic-substituted fused heteroaryls, a pharmaceutical composition based thereon
TW200300673A (en) Azabicyclic-phenyl-fused-heterocyclic compounds for treatement of disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050603

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060418